Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches
eBioMedicine · 2025
DOI: 10.1016/j.ebiom.2025.105751 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift eBioMedicine, 2025. Verfasst von Ana Pilar Gómez-Escribano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomé…. Hauptthemen laut MEDLINE: Retinal Dystrophies, Genetic Therapy, RNA, DNA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Valencia Department of Education Culture and Sport, Instituto de Salud Carlos III, Biomedical Research Network Centre of Bioengineering Biomaterials and Nanomedicine.
Abstract (Originalsprache)
Gene therapy has become a promising treatment for inherited retinal dystrophies (IRDs), but understanding the genetic mechanisms involved is essential for its success. Various approaches, such as gene augmentation and DNA/RNA-based therapies, have shown effectiveness in some clinical trials. However, gene augmentation is not effective for some dominant mutations and genome editing produces off-target effects. Here, we review safer and viable alternatives that are being evaluated in preclinical models and clinical trials to address this challenge. We propose a novel perspective based on protein-targeting therapies, which although promising, remain unexplored. We suggest that frameshift variants, which produce novel epitopes, may allow for the development of mutant protein targeting agents for selective protein degradation. This approach could be useful for dominant variants, where gene replacement is ineffective. By examining these approaches, we aim to guide more targeted and effective gene therapies for IRDs, offering potential treatments where current methods fall short.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain; Joint Un…
- Centenara labs, Zürich, Suiza, Switzerland.
Förderung
- Valencia Department of Education Culture and Sport
- Instituto de Salud Carlos III
- Biomedical Research Network Centre of Bioengineering Biomaterials and Nanomedicine
- European Regional Development Fund
Zitieren
APA
Gómez-Escribano, A. P., García-García, G., Pérez-Santamarina, E., Aller-Mañas, E., Vázquez-Manrique, R. P., & Millán-Salvador, J. M. (2025). Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches. eBioMedicine. https://doi.org/10.1016/j.ebiom.2025.105751
Vancouver
Gómez-Escribano AP, García-García G, Pérez-Santamarina E, Aller-Mañas E, Vázquez-Manrique RP, Millán-Salvador JM. Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches. eBioMedicine. 2025. doi:10.1016/j.ebiom.2025.105751
BibTeX
@article{GmezEscribano2025,
author = {Gómez-Escribano, Ana Pilar and García-García, Gema and Pérez-Santamarina, Estela and Aller-Mañas, Elena and Vázquez-Manrique, Rafael Pascual and Millán-Salvador, José María},
title = {Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches},
journal = {eBioMedicine},
year = {2025},
doi = {10.1016/j.ebiom.2025.105751}
}
EUVIMED